<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774640</url>
  </required_header>
  <id_info>
    <org_study_id>SQNM-T21-306</org_study_id>
    <nct_id>NCT04774640</nct_id>
  </id_info>
  <brief_title>Development of a NIPTT for Detecting Copy Number Variations</brief_title>
  <official_title>Noninvasive In Vitro Diagnostic Test For Fetal Chromosomal Abnormality: Assay Development and Optimization in Affected Pregnancies With Abnormal Microarray Findings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequenom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sequenom, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect whole blood samples from pregnant women for the purpose of developing, optimizing&#xD;
      and evaluating laboratory-developed noninvasive prenatal test (NIPT) for the detection of&#xD;
      fetal chromosomal abnormalities of interest defined as microinsertions, microdeletions and&#xD;
      other copy number variations (CNVs). The NIPT result will be compared to the test results&#xD;
      obtained by microarray analysis of fetal cellular material obtained by amniocentesis or&#xD;
      chorionic villus sampling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center specimen collection study. Eligible subjects from across the USA will&#xD;
      be referred to the single center for participation.&#xD;
&#xD;
      This study will evaluate whether the test methods being developed for the detection of fetal&#xD;
      chromosomal abnormalities of interest in maternal whole blood samples can be used in clinical&#xD;
      practice.&#xD;
&#xD;
      Enrollment of study subjects will be done in two phases - an initial pilot study phase to&#xD;
      collect samples for research and development activities, followed by a larger single-blinded&#xD;
      sample collection phase for NIPT evaluation. For both phases, study subjects will be enrolled&#xD;
      in a prospective manner until the predetermined sample size is attained. Each study subject&#xD;
      will be asked to provide one 20mL blood sample.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor rate of eligible subject enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">May 29, 2014</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of non-invasive pregnancy test (NIPT)</measure>
    <time_frame>5 years</time_frame>
    <description>NIPT results will be compared to test results obtain by microarray analysis of fetal cellular material obtained by amniocentesis or chorionic villus sampling</description>
  </primary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Copy Number Variations</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MaterniT GENOME</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal plasma with cell free fetal DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women with a fetus previously determined by microarray to have a chromosomal&#xD;
        abnormality of interest..&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is female&#xD;
&#xD;
          -  Subject is 18 years of age or older&#xD;
&#xD;
          -  Subject is pregnant at no less than 10 weeks and no more than 36 weeks gestation&#xD;
&#xD;
          -  Subject provides a signed and dated informed consent&#xD;
&#xD;
          -  Subject has a current pregnancy in which the fetus is determined to have a chormosomal&#xD;
             abnormality of interest (microinsertions, microdeletions and other CNVs) as determined&#xD;
             by microarray analysis of fetal cellular material obtained by IP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has experienced fetal demise in the current pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Subjects must be pregnant</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

